Nerandomilast improved FVC in the FIBRONEER-ILD trial, meeting its primary end point in patients with progressive pulmonary fibrosis. Safety and tolerability results were consistent with previous ...

MANILA, Philippines — Navigating the complexities of Interstitial Lung Disease (ILD)—a group of disorders characterized by scarring and inflammation of lung tissue—can be overwhelming ...

The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...

Of the patients who transitioned from pediatric to adult ILD centers, significant adjustments were made to diagnoses for 9.8% and to treatment for 16.0%. Children diagnosed with interstitial lung ...

Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with RA. Notably, RA-ILD shares several risk factors with idiopathic pulmonary fibrosis (IPF), namely male ...

Objectives To estimate lifetime risk of developing rheumatoid arthritis-associated interstitial lung disease (RA-ILD) with respect to the strongest known risk factor for pulmonary fibrosis, a MUC5B ...